Indian panel outlines principles for review of essential drugs list
This article was originally published in Scrip
An eight-member expert panel mandated to review India's national list of essential medicines (NLEM) 2011 has put forth a first draft of ''guiding principles'' for the exercise, including a specific suggestion that the annual sales figures of drugs should not be a consideration while including medicines in the list of essential drugs.
You may also be interested in...
Dr Reddy’s management clears air on ransomware attack and says all critical operations are being enabled in a 'controlled and cautious' manner. The Indian firm also shared a timeline for its partnered Russian COVID-19 vaccine amid a free supply chorus in India.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.